The available evidence shows that eculizumab is effective in reducing complement-mediated hemolysis. The evidence is not very strong since there is no CRCT conducted on prevention of thrombotic events. It has not been determined if eculizumab therapy increases survival of PNH patients yet.
Although some private insurance companies in the United States give coverage to certain patients, most health systems in different countries do not cover it due to its high costs and because it provides marginal benefits when compared with standard care for PNH.